We investigated whether microRNAs (miRNAs) may serve as an alternative biomarker of fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor (TKI) sensitivity in lung cancer cell lines. A miRNA panel (let-7c, miRNA155, and miRNA218) could be useful in predicting response to FGFR TKIs, either ponatinib or AZD4547. Purpose: To test whether a microRNA (miRNA) panel may serve as an alternative biomarker of fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor sensitivity in lung cancer. Methods: Histologically diverse lung cancer cell lines were submitted to assays for ponatinib and AZD4547 sensitivity. miRNAs, FGFR1 messenger RNA, gene copy number, and protein expression were detected by real-time quantitative PCR, fluorescence in-situ hybridization, and immunoblotting in 34 lung cancer cell lines. Results: Among 34 cell lines, 14 exhibited ponatinib sensitivity and 20 exhibited AZD4547 sensitivity (drug concentration causing 50% inhibition values < 100 nmol/L). A total of 39 of the 377-miRNA set were initially identified from the 4 paired ponatinib-sensitive or -insensitive cell lines to have at least an 8-fold differential expression and then were detected in all the 34 cell lines. A predictive panel of 3 miRNAs (let-7c, miRNA155, and miRNA218) was developed that had an area under the curve (AUC) of 0.886 with a sensitivity of 71.4% and specificity of 77.3% to predict response to ponatinib. The miRNA panel performed similar to FGFR1 protein expression (AUC ¼ 0.864) and messenger RNA expression (AUC ¼ 0.939), and better than FGFR1 amplification (AUC ¼ 0.696). Furthermore, we validated this panel using data for sensitivity to AZD4547 in the cell line cohort with an AUC of 0.931 and a sensitivity of 73.3% and specificity of 76.2%, respectively. Conclusion: The developed miRNA panel (let-7c, miRNA155, and miRNA218) may be useful in predicting response to FGFR tyrosine kinase inhibitors, either ponatinib or AZD4547 in lung cancer cell lines, and warrants further validation in the clinical setting.
Introduction
The fibroblast growth factor receptor (FGFR) pathway is an important oncogenic driver in malignant cancer. 1 It controls cellular processes such as cell proliferation, differentiation, migration, cycle progression, metabolism, and survival. In nonesmall-cell lung cancer, the most frequent alteration of the FGFR pathway is represented by FGFR1 amplification, which is reported as occurring in up to 20% of squamous nonesmall-cell lung cancer; other, less frequent alterations include point mutations or translocations of the genes encoding for FGFR1-4.
and BJG398 (Novartis, Basel, Switzerland). 6 In these studies, preliminary results showed that only a subset of patients with FGFR amplification or protein overexpression had disease that responded to the FGFR tyrosine kinase inhibitors (TKIs) AZD4547 and BJG003. 5, 6 The response rates did not reach those observed for other lung cancer driver mutation genes, such as mutant EGFR or ALK/ROS1 fusion, suggesting that the biomarkers used for enrolling onto the FGFR TKI trials were inaccurate. 7 In a set of 58 lung cancer cell lines, sensitivity to ponatinib was correlated with FGFR1 amplification, messenger RNA (mRNA) and protein expression, and mRNA expression of FGF2 and FGF9. 8 This study reported better correlation of FGFR1 TKI sensitivity with FGFR1 mRNA or protein expression compared to FGFR1 amplification. These data clearly identify the need for further investigation to find additional biomarkers that may be better able to predict response to FGFR inhibitors in the clinical setting. MicroRNAs (miRNAs) are small, noncoding, stable sequences of RNA with regulatory functions exerted through inhibition of crucial mRNA. 9 Recent studies demonstrated that pathologic conditions, such as solid tumors, are associated with specific intracellular miRNA patterns and are also able to affect circulating miRNA. On the basis of this assumption, several studies have identified specific miRNAs or groups of miRNAs (miRNA signatures) with a potential diagnostic or prognostic role in solid tumors. 10, 11 Some miRNAs, such as miR34bc, are currently considered promising predictors of poor outcome for early-stage lung cancer, apparently as a result of a correlation between their target genes inactivation and an aggressive phenotype. 12 Another study suggested the existence of a circulating miRNA signature able to detect lung cancer. 13 Furthermore, our previous study also found miRNA signatures were also reported as able to predict the sensitivity of lung cancer to epidermal growth factor receptor (EGFR) TKIs. 14, 15 In this present study, we performed a comprehensive analysis of miRNAs in a panel of human lung cancer cell lines that were previously characterized for sensitivity to 2 FGFR1 TKIs. 8 We developed a 3-miRNA panel that accurately predicts the sensitivity to ponatinib in 34 cell lines and the chemically distinct TKI, AZD4547.
Methods

Cell Culture
All cell lines were cultured in RPMI 1640 growth medium supplemented with 10% fetal bovine serum at 37 C in a humidified 5% CO 2 incubator. The following cell lines were available in our laboratories and submitted to DNA fingerprint analysis for authentication: H1703, HCC95, NE-18, DMS-114, SKMES-1,  H460, SW1573, H520, H661, H125, HCC44, H1299, H157,  Colo699, H1581, HCC15, H2126, H1869, H1435 , and H441. The remaining 14 cell lines were obtained directly from the University of Colorado Cancer Center Tissue Culture Core (Aurora, CO). The core laboratory routinely performs DNA fingerprint analyses on all banked cell lines to ensure their authenticity.
Analysis of Ponatinib and AZD4547 in Cell Lines
Sensitivity to ponatinib was defined as a drug concentration causing 50% inhibition (IC 50 ) of 100 nM/L in a cohort of cell lines that were previously characterized for FGF ligand and FGFR receptoremediated autocrine signaling status. 8, 16 The IC 50 for AZD4547 was also determined in the lung cancer cell lines, including 13 ponatinib-sensitive cell lines and 44 ponatinibresistant cell lines by using the IC 50 cutoff value of 100 nM/L. Cell line information is presented in Supplemental Table 1 in the online version.
Real-Time Quantitative PCR for miRNA Analysis
We used a comprehensive, commonly employed commercial panel (TaqMan Array Human MicroRNA A Card v2.0; Life Technologies, Carlsbad, CA) to perform the miRNA expression level detection; this panel utilizes a 384-well microfluidic card, enabling the testing of 377 miRNAs plus 3 provided endogenous controls and 1 nonhuman negative control.
Initially, 4 lung cancer cell lines determined to be sensitive to ponatinib (Colo699, H1581, SW1573, and H520) were selected as well as 4 insensitive cell lines (H125, NE-18, H2126, and SK-MES-1) and were analyzed for miRNA expression. RNA was extracted from treatment-naive cell cultures, and real-time quantitative polymerase chain reaction (qPCR) was performed using a 7900HT Fast Real-Time cycler (Applied Biosystems; Thermo Fisher Scientific, Waltham, MA). Cycle thresholds (DC t ) were normalized using U6 small nuclear RNA as per the manufacturer's protocol. Each cell line was analyzed in triplicate and averaged data generated. In order to determine the DC t , the threshold was set at 0.2, and baseline data collected at cycles 3 to 15. On the basis of the results of the qPCR, a statistical analysis of microarrays (SAM) plot analysis was performed (Stanford University; http://statweb. stanford.edu/wtibs/SAM/,) which identified the 39 most differentially expressed miRNAs from the original set of 377. Here miRNAs that exhibited an 8-fold expression difference between sensitive and insensitive cell lines were included. After selection, the panel of 39 miRNAs was then assayed across the 34 lung cancer cell lines.
8
FGFR1 Protein, mRNA Expression, and Gene Copy Number Detection
Selected lung cancer cell lines were submitted to the University of Colorado Cancer Center Molecular Pathology shared resource for evaluation of FGFR1 gene copy number by fluorescence in-situ hybridization (FISH) analysis. FGFR1 protein and mRNA levels were measured by immunoblotting with an antibody against the carboxyl-terminus of FGFR1 and qPCR with primers annealing to sequences within the invariant second immunoglobulin domain. The methods for FISH, protein immunoblotting, and qPCR have been described previously. 8 
Transfection of let-7c Inhibitor
On the basis of the observed data, the interaction between the most relevant miRNA, let-7c, and the status of FGFR1 mRNA expression were further explored through an additional experiment. We included 11 ponatinib-sensitive cell lines treated with let-7c inhibitor and its negative control oligonucleotide (Invitrogen; Thermo Fisher Scientific). Cells were added to 6-well plates (2 Â 10 5 cells per well) and transfected with miRNA inhibitor using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific) according to the manufacturer's protocol. After 72 hours, cells were collected and tested for alternations in the levels of specific miRNA and FGFR1 mRNA by qPCR.
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Statistical Analysis
We assessed the expression of miRNAs for classification of lung cancer cells as sensitive or insensitive to ponatinib using logistic regression by computing the receiver operating characteristic (ROC) curve and used the area under the ROC curve (AUC) as an accuracy index. Among potential biomarkers, miRNAs characterized by a statistical P < .1 in the univariate analysis were selected to enter into multivariable logistic regression, which were selected in a combination of biomarkers potentially able to predict sensitivity to ponatinib. We further validated the biomarker panel for a distinct FGFR inhibitor, AZD4547, in the same cell line cohort. All P values were 2 sided, with values < .05 considered statistically significant. SAS 9.3 (SAS Institute, Cary, NC) and SPSS 21.0 (IBM, Armonk, NY, USA) were used for the statistical analyses.
Results
Cell Lines and Their Sensitivity to Ponatinib and AZD4547
The IC 50 for ponatinib and AZD4547 are listed in Supplemental Table 1 in the online version. We used our previous criteria to distinguish ponatinib-sensitive cell lines (IC 50 100 nM) from ponatinib-resistant cell lines and identified 14 ponatinib-sensitive cell lines and 20 ponatinib-resistant cell lines. 11 As for AZD4547, Tables 2 and 3 , respectively, in the online version. SAM analysis identified 39 miRNAs that have more than an 8-fold difference in expression, which were used in subsequent investigations in the 34 cell lines (Table 1) . Univariate analysis identified 8 distinct miRNAs whose concentration was significantly or marginally significantly associated with sensitivity to ponatinib, including let-7c, miR155, miR218, miR3383p, miR200b, miR379, miR200c, and miR429 (Table 1) . Because of the limited cell lines included in this study, we performed the ROC curve analysis with the above 8 individual miRNAs and found that miR200c or miR429 alone was not significantly predictive of the sensitivity to ponatinib in cell lines. Finally, let-7c, miR155, miR218, miR3383p, miR200c, miR379, and miR200b were evaluated by multivariate analysis and allowed the identification of a miRNA panel associated with sensitivity to ponatinib, including increasing let-7c, increasing miR-218, and decreasing miR-155. This 3-miRNA panel was associated with a model AUC ¼ 0.886 with a sensitivity of 71.4% and specificity of 77.3% to predict the response to ponatinib. The ROCs are depicted in Figure 1 .
Comparing Developed miRNA Panel With Other Biomarkers Including FGFR mRNA, Protein Expression, and Amplification
In a previous study, we found that FGFR mRNA or FGFR protein expression, but not FGFR amplification, was associated with sensitivity to ponatinib in lung cancer cell lines. 8 These biomarkers
were studied in all 34 cell lines deployed in the present study. Similar to our previous reports, we found that FGFR1 mRNA or FGFR1 protein expression could predict sensitivity to ponatinib, with AUCs of 0.939 and 0.864, respectively. We determined that 
miRNA Predicts Sensitivity of FGFR Inhibitor
FGFR amplification predicts sensitivity to ponatinib with an AUC of 0.696. The 3-miRNA panel developed in this study has an AUC of 0.886, which is similar to the sensitive biomarkers of FGFR1 mRNA or FGFR1 protein expression in the study (Figure 1 ).
Validating 3-miRNA Panel and Evaluating Other Biomarkers for Sensitivity to AZD4547 in Cell Line Cohort
Data for sensitivity to AZD4547 were established for 33 out 34 study cell lines. Here we chose to evaluate the same concentration for AZD4547 that was used for ponatinib (100 nM), resulting in the identification of 13 sensitive and 20 resistant cell lines for the validation cohort. The 3-miRNA panel developed for ponatinib predicted cell line sensitivity to AZD4547 with an AUC of 0.931, sensitivity of 73.3%, and specificity of 76.2%. We further investigated the biomarkers of FGFR1 mRNA, and protein expression and amplification in the setting of the cohort of 34 cell lines. Analysis revealed that FGFR1 mRNA or FGFR1 protein expression could predict the sensitivity of AZD4547, with AUCs of 0.871 and 0.735, respectively, while FGFR amplification was less able to predict the sensitivity of ponatinib, with an AUC of 0.585 (Figure 1 ).
Comparing Distinguished Yield of miRNA Panel Using Different IC 50 Cutoffs
We further investigated whether the miRNA panel exhibits a consistent distinguished yield by using a different IC 50 cutoff. When 50 nM was used as the IC 50 cutoff value for both ponatinib and AZD4547, 13 ponatinib-sensitive and 21 ponatinib-resistant cell lines were identified, while 8 sensitive and 25 resistant cell lines were identified for AZD4547. This 3-miRNA panel was associated with a model AUC ¼ 0.853 to predict the response to ponatinib. The 3-miRNA panel developed for ponatinib predicted cell line sensitivity to AZD4547 with an AUC of 0.865. These results using the cutoff value of 100 nM were consistent with those for both ponatinib and AZD4547 (Figure 2 ).
Relationship of let-7c With FGFR1 mRNA Expression
Because let-7c was the most robust miRNA in the univariate analysis (in terms of P value), it was considered the best candidate for studying interactions with FGFR1 mRNA. Experiments used transient transfection with a let-7c silencing RNA (Life Technologies) to explore effects of let-7c levels on FGFR1 mRNA expression. In these experiments, the high mobility group AT-hook 2 (HMGA2) gene served as a surrogate measurable target of repression exerted by let-7c. 17, 18 After 72 hours, 6 of 11 cell lines showed an increase in HMGA2 levels (reflecting a decrease in let-7c levels); of these 6 cell lines, 5 also showed a reduction in FGFR1 mRNA levels from baseline (Table 2) .
Discussion
Precision therapy, guided by biomarkers of response, has dramatically improved the prognosis of patients with advanced lung cancer. 19 Examples include mutant EGFR that can be effectively inhibited by EGFR TKIs, and deficient mismatch 
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Clinical Lung Cancer September 2018 -453 repair and high microsatellite instability, which are susceptible to antiePD-1 immunotherapy. [20] [21] [22] In this study, we investigated the role of miRNAs as a biomarker to predict sensitivity to FGFR inhibitors. Analysis revealed differences in the miRNA expression between cell lines determined to be sensitive and resistant to ponatinib with identification of a predictive miRNA panel including let-7c, miRNA155, and miRNA218. Analysis of this panel identified an AUC of 0.886 to predict sensitivity to ponatinib, which is as good as other predictive biomarkers including FGFR1 mRNA and protein expression, as previously reported. 8 Furthermore, the predictive role of this miRNA panel was validated when comparing sensitivity of AZD4547 in the cell line cohort. Moreover, we found that the mechanism of let-7c to predict the sensitivity of ponatinib may involve regulating the mRNA expression of FGFR1. After the successful development of molecular targeted drugs in lung adenocarcinoma, substantial efforts have been made to provide similar targeted drugs in lung squamous-cell carcinoma. 23 Because FGFR gene alteration is the most frequent occurrence in squamouscell carcinoma, targeted therapies for FGFR including ponatinib, AZD4547, and BJG003 are being evaluated. [4] [5] [6] Preliminary clinical data found that only a small subset of enrolled patients have disease that responds to these FGFR1 TKIs. One potential explanation may be the improper use of FGFR amplification as a patient selection biomarker. 7 As identified in our previous study, FGFR1 mRNA or protein expression, but not gene copy number, better predicts FGFR TKI sensitivity across all lung cancer cell line studies. 8 These previous data suggested the need for better biomarkers to predict tumor sensitivity to targeted drugs. Currently, efforts to identify patients who are likely to experience anticancer treatment failure are ongoing, and evaluations of miRNA dysregulation to support this endeavor have been reported. 24 27 Thus, our miRNA panel might be better than FGFR1 mRNA or protein expression if this miRNA panel in circulating miRNA was identified as a reliable predictive factor for screening patients for FGFR1 inhibitor-which is our next research step in the near future. In addition, the 34 cell lines included into this study contained different histologic subtypes such as adenocarcinoma, squamouscell, large-cell, and small-cell cell lines without known oncogenic mutations, which might not represent the whole lung cancer population. However, because FGFR1 inhibitors are rarely effective in patients with EGFR/ALK/ROS1 mutation, investigation of the biomarker for FGFR1 inhibitor in oncogenic driver pan-negative cell lines will be helpful in identifying a potential one with clinical applications. Additionally, because let-7c was the most robust miRNA in the univariate analysis to predict sensitivity to ponatinib, we further investigated the correlation between let-7c and FGFR1 mRNA. We found that let-7c silencing was significantly associated with decreased expression of FGFR1, suggesting that let-7c predicts, but also participates in, regulation of FGFR1 mRNA levels and thereby sensitivity to ponatinib. It has been reported that let-7 has been demonstrated to be a direct regulator of RAS 28 and HMGA2 expression 29 in human cells through binding sequences in their 3 0 untranslated regions. However, the detailed mechanism of let-7c and correlated changes in FGFR1 mRNA is still unknown and warrants further investigation.
Conclusion
This study comprehensively evaluated the predictive role of miRNA to FGFR inhibitors in 34 cell lines. Further, we developed a miRNA panel (let-7c, miRNA155, and miRNA218) that was validated with sensitivity to AZD4547 in the cell line cohort. Similar to FGFR1 mRNA or protein expression, the miRNA panel predicted the sensitivity of ponatinib and AZD4547. Because the miRNA panel could also be detected by a noninvasive liquid biopsy, we plan to further explore its role for predicting sensitivity to FGFR TKIs in the clinical setting.
Clinical Practice Points
The improper use of FGFR amplification as a patient selection biomarker might be a potential explanation for the preliminary clinical data that found that only a small subset of enrolled patients had disease that responded to these FGFR1 TKIs. Our previous study found that FGFR1 mRNA or protein expression, but not gene copy number, better predicts FGFR TKI sensitivity across all lung cancer cell line studies. This study found that a miRNA panel (let-7c, miRNA155, and miRNA218) could predict the sensitivity of FGFR TKIs for not only ponatinib but also AZD4547.
